An open-label, two-part, single sequence study to examine the effects of lapatinib on the pharmacokinetics of orally administered digoxin in subjects with metastatic ErbB2 [erythroblastic leukemia viral oncogene homolog 2] positive breast cancer.

Trial Profile

An open-label, two-part, single sequence study to examine the effects of lapatinib on the pharmacokinetics of orally administered digoxin in subjects with metastatic ErbB2 [erythroblastic leukemia viral oncogene homolog 2] positive breast cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Lapatinib (Primary) ; Digoxin
  • Indications Advanced breast cancer
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Jul 2010 Actual patient number (17) added as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Actual end date (July 2009) added as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top